Developer docs
API playgroundTry for free, no card

Search company profiles

CardioFocus

Full company profile

uuid0000qlh

Namestring
CardioFocus
Legal namestring
CardioFocus, Inc.
Websiteurl
cardiofocus.com
Company typeenum
Private
Founded yearint
2000
Descriptiontext

CardioFocus is a privately held medical device company headquartered in Marlborough, Massachusetts (Delaware-incorporated), developing Pulsed Field Ablation (PFA) systems for the treatment of cardiac arrhythmias, with a primary focus on atrial fibrillation. The company's core technology combines proprietary waveform science — most notably the WAVE1 monopolar biphasic waveform — with co-engineered catheter and generator platforms. Its portfolio includes the commercially available Centauri System (CE-marked in select EU countries), the legacy FDA-approved HeartLight X3 endoscopic ablation system, and three investigational next-generation systems: QuickShot Nav (large-area focal PFA catheter with integrated mapping), OptiShot (single-shot PFA balloon with endoscopic visualization), and CardioWave (modular generator designed to power multiple catheter types). The company reports over 10,000 patients treated worldwide with the HeartLight platform and serves electrophysiologists performing pulmonary vein isolation procedures.

CardioFocus operates an enterprise field sales model targeting hospitals and electrophysiology labs, supplemented by a network of regional distribution partners for international markets: Japan Lifeline (Japan, since 2015 and deepened via a 2025 strategic alliance), MicroPort CRM (Spain and Portugal), China Grand Pharmaceutical (China), and BIOTRONIK (European expansion, 2024). The company sells hardware — ablation catheters, generators, and accessories — through quote-based hospital procurement processes, and generates incremental revenue through distribution and licensing arrangements with regional partners. Pricing is not publicly disclosed.

The company has raised over $200 million cumulatively since inception across multiple venture, debt, and equity rounds, including a $55 million financing in 2019 led by Kennedy Lewis Investment Management and SEC Form D filings of approximately $50 million (2022) and $31.76 million (2023). Recent strategic actions include the January 2024 acquisition of the Electrophysiology Division of Galvanize Therapeutics to expand PFA intellectual property, and a series of 2024–2026 partnerships with Stereotaxis (robotic PFA), LUMA Vision (4D imaging-guided ablation), and the expansion of CE Mark and US IDE clinical programs across Europe and the United States.

Short descriptiontext

CardioFocus is a privately held medical device company that develops Pulsed Field Ablation (PFA) catheter and generator systems for treating cardiac arrhythmias, primarily atrial fibrillation, serving electrophysiologists and EP hospitals in the US, EU, Japan, and China.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMarlborough, United States
HQ citystring
Marlborough
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pulsed field ablation, cardiac ablation catheters, electrophysiology medical devices, atrial fibrillation treatment, cardiac arrhythmia therapy
Industry2 codes
PRIMARYHLAHAFAD
Electrophysiology Mapping & Ablation Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAC
Electrophysiology (Heart Rhythm)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cardiac Electrophysiology Devices
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1PFA Catheter Systems
TypeHardware Sales
Description

CardioFocus generates revenue from the sale of pulsed field ablation catheter systems including the Centauri System (CE-marked, commercially available in EU) and investigational systems (QuickShot Nav, OptiShot, CardioWave). Revenue comes from selling ablation catheters, generators, and associated accessories to hospitals and electrophysiology labs.

cardiofocus.com
2Distribution Partnerships
TypeLicensing Royalties
Description

Revenue generated through distribution agreements with regional partners including Japan Lifeline (Japan distribution), MicroPort CRM (Spain and Portugal), China Grand Pharmaceutical (China), and BIOTRONIK (European expansion). Partners distribute CardioFocus products in their respective territories.

cardiofocus.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Centauri
Description

CE-marked open-platform pulsed field ablation system with custom monopolar waveform for cardiac tissue ablation.

cardiofocus.com
+4 more records
Core offering1 text field

CardioFocus develops and manufactures pulsed field ablation (PFA) catheter systems and generators for treating cardiac arrhythmias, primarily atrial fibrillation. Its portfolio includes the CE-marked Centauri System (open-platform focal PFA with proprietary WAVE1 waveform) and investigational next-generation systems including QuickShot Nav (large-area focal catheter with map-and-ablate capability), OptiShot (single-shot PFA balloon with endoscopic visualization), and CardioWave (modular multi-catheter generator). The products are sold to hospitals and electrophysiology labs for pulmonary vein isolation procedures.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 89% PV isolation at 3 months using Centauri System across three compatible ablation catheters
+5 more records
Product overview1 text field

CardioFocus develops a portfolio of Pulsed Field Ablation (PFA) systems for treating cardiac arrhythmias, particularly atrial fibrillation. The portfolio includes the CE-marked Centauri System (open-platform focal PFA with three selectable doses and compatibility with major mapping systems), alongside next-generation investigational systems: QuickShot Nav (large-area focal catheter), OptiShot (single-shot PFA balloon with endoscopic visualization), and CardioWave (modular multi-catheter generator). The company previously offered the HeartLight laser balloon system, which has been succeeded by the PFA portfolio. All systems are designed for pulmonary vein isolation procedures and integrate with established electrophysiology lab workflows.

Product and service5 records
1Centauri System
CategoryPFA Generator System
Description

An open-platform pulsed field ablation system that integrates into established electrophysiology workflows, delivering a custom monopolar waveform (WAVE1) to create durable lesions safely and efficiently. CE-marked and available in select EU countries, with compatibility across major mapping systems (EnSite X, Carto 3, Rhythmia HDx) and contact force catheters.

2QuickShot Nav
CategoryPFA Catheter
Description

A versatile large-area focal PFA catheter designed to map and ablate with a single, integrated device, uniting mapping and ablation into one streamlined workflow for addressing complex cardiac arrhythmias.

3OptiShot
CategoryPFA Balloon Catheter
Description

An ultra-compliant pulsed field ablation balloon with direct endoscopic visualization, enabling circumferential therapy from a single position with a single energy application per vein for pulmonary vein isolation, with anatomy-adaptive balloon architecture.

4CardioWave System
CategoryPFA Generator System
Description

A modular, next-generation PFA generator engineered to power multiple catheter types and clinical applications from a single system, built on proven Centauri technology.

5HeartLight Endoscopic Ablation System
CategoryLegacy Laser Balloon Ablation System
Description

Legacy laser balloon ablation system for treatment of atrial fibrillation, FDA-approved in 2016 and superseded by the company's PFA portfolio.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2026-01-07
Description

Clinical study collaboration in which LUMA Vision's VERAFEYE 4D Imaging Platform was used with CardioFocus ablation systems. Study demonstrated VERAFEYE's ability to integrate high-resolution intracardiac imaging with CardioFocus PFA technology, enabling streamlined two-catheter ablation workflow.

Strategic tierMajorTypeTechnology or IntegrationAnnounced on2025-10-13
Description

Collaboration to advance robotic Pulsed Field Ablation (PFA) technology for cardiac arrhythmias. Joint effort aims to accelerate commercialization of combined robotic PFA system, with preclinical testing showing promising results.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-07-24
Description

Partnership to expand pulsed field ablation access in Europe. BIOTRONIK will distribute CardioFocus PFA products to expand market reach across European territories.

4Japan Lifeline
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-02-28
Description

Strategic alliance to advance differentiated PFA system in Japan. Japan Lifeline has been a distribution partner for CardioFocus HeartLight system since 2015, with expanded partnership in 2018 and 2021. The partnership covers distribution of PFA products in Japan.

cardiofocus.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-01-11
Description

CardioFocus acquired the Electrophysiology Division of Galvanize Therapeutics, including key intellectual property assets that strengthen CardioFocus's PFA technology portfolio.

6China Grand Pharmaceutical
Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-06-04
Description

Agreement to bring HeartLight X3 System to China. China Grand Pharmaceutical serves as distribution partner for the Chinese market.

cardiofocus.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-01-11
Description

Expanded distribution partnership to include Spain and Portugal for HeartLight System distribution. MicroPort CRM covers key European markets.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeRegional player
Description

European distribution partner for CardioFocus PFA products (announced July 2024) and a broader cardiac rhythm management device manufacturer. Comparable as a CRM and ablation-adjacent player with strong European EP footprint that channels CardioFocus into hospitals.

TypeDirect peer
Description

Direct competitor via PulseSelect single-shot PFA catheter and the Affera mapping-and-ablation platform acquired in 2022. Medtronic is a major incumbent with global EP sales force and bundled mapping (CardioInsight) competing head-to-head in the PFA category.

3Acutus Medical
TypeEmerging player
Description

Emerging player in electrophysiology with novel mapping technology and ablation catheter development, including PFA-related programs. Compares to CardioFocus as a smaller, technology-focused EP innovator competing against larger integrated incumbents.

TypeDirect peer
Description

Direct competitor through its Farapulse pulsed field ablation system, which has been one of the earliest commercialized PFA platforms globally. Boston Scientific's scale, US sales force, and integrated mapping (OPAL HDx) compete directly with CardioFocus's Centauri System in EP labs.

TypeRegional player
Description

Distribution partner for CardioFocus HeartLight in Spain and Portugal (announced 2021) and broader CRM/cardiac device manufacturer. Comparable as a regional EP-focused player serving Iberian markets where CardioFocus relies on partner-led commercialization.

TypeEmerging player
Description

Robotic magnetic navigation ablation partner of CardioFocus (announced October 2025) developing robotic PFA workflows. Comparable as an EP technology enabler serving the same electrophysiology lab customers CardioFocus targets.

7Johnson & Johnson (Biosense Webster)
TypeDirect peer
Description

Direct competitor with the Varipulse pulsed field ablation catheter and CARTO 3 mapping system — a dominant EP franchise worldwide. CardioFocus's Centauri is explicitly compatible with CARTO 3, meaning J&J is both a partner-enabler and a direct competitor in PFA.

8Japan Lifeline
TypeRegional player
Description

Japanese distribution partner for CardioFocus HeartLight since 2015 and now strategic PFA alliance partner (February 2025). Comparable as a regional EP/cardiac rhythm distributor addressing the Japanese market CardioFocus does not serve directly.

9Adagio Medical
TypeEmerging player
Description

Emerging player developing ultra-low temperature cryoablation and pulsed field technologies for atrial fibrillation. Adagio's iCLAS catheter and cryo-PFA approach represent an alternative single-shot strategy, partially overlapping with CardioFocus's OptiShot balloon platform.

10Abbott
TypeDirect peer
Description

Direct competitor through Abbott's TactiFlex Sensor Enabled and Volt PFA catheters targeting atrial fibrillation ablation. Abbott's EnSite X mapping system is a key integration partner for CardioFocus's Centauri, mirroring the J&J dynamic of partnership plus competition.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration9 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds19 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CardioFocus

Cardiac Electrophysiology Devicescardiofocus.com

CardioFocus is a privately held medical device company that develops Pulsed Field Ablation (PFA) catheter and generator systems for treating cardiac arrhythmias, primarily atrial fibrillation, serving electrophysiologists and EP hospitals in the US, EU, Japan, and China.

What CardioFocus does

CardioFocus is a privately held medical device company headquartered in Marlborough, Massachusetts (Delaware-incorporated), developing Pulsed Field Ablation (PFA) systems for the treatment of cardiac arrhythmias, with a primary focus on atrial fibrillation. The company's core technology combines proprietary waveform science — most notably the WAVE1 monopolar biphasic waveform — with co-engineered catheter and generator platforms. Its portfolio includes the commercially available Centauri System (CE-marked in select EU countries), the legacy FDA-approved HeartLight X3 endoscopic ablation system, and three investigational next-generation systems: QuickShot Nav (large-area focal PFA catheter with integrated mapping), OptiShot (single-shot PFA balloon with endoscopic visualization), and CardioWave (modular generator designed to power multiple catheter types). The company reports over 10,000 patients treated worldwide with the HeartLight platform and serves electrophysiologists performing pulmonary vein isolation procedures.

CardioFocus operates an enterprise field sales model targeting hospitals and electrophysiology labs, supplemented by a network of regional distribution partners for international markets: Japan Lifeline (Japan, since 2015 and deepened via a 2025 strategic alliance), MicroPort CRM (Spain and Portugal), China Grand Pharmaceutical (China), and BIOTRONIK (European expansion, 2024). The company sells hardware — ablation catheters, generators, and accessories — through quote-based hospital procurement processes, and generates incremental revenue through distribution and licensing arrangements with regional partners. Pricing is not publicly disclosed.

The company has raised over $200 million cumulatively since inception across multiple venture, debt, and equity rounds, including a $55 million financing in 2019 led by Kennedy Lewis Investment Management and SEC Form D filings of approximately $50 million (2022) and $31.76 million (2023). Recent strategic actions include the January 2024 acquisition of the Electrophysiology Division of Galvanize Therapeutics to expand PFA intellectual property, and a series of 2024–2026 partnerships with Stereotaxis (robotic PFA), LUMA Vision (4D imaging-guided ablation), and the expansion of CE Mark and US IDE clinical programs across Europe and the United States.

CardioFocus firmographics

Firmographics
Name
CardioFocus
Legal name
CardioFocus, Inc.
Website
https://cardiofocus.com
Company type
Private
Founded year
2000
Operating status
Operating
Headcount range
51–100 employees
Short description
CardioFocus is a privately held medical device company that develops Pulsed Field Ablation (PFA) catheter and generator systems for treating cardiac arrhythmias, primarily atrial fibrillation, serving electrophysiologists and EP hospitals in the US, EU, Japan, and China.
Ownership category
akta.pro rank

CardioFocus industry classification

Industry
Product category
Cardiac Electrophysiology Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAFAD
Electrophysiology Mapping & Ablation Systems
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAKABAC
Electrophysiology (Heart Rhythm)

Keywords

  • Pulsed field ablation
  • Cardiac ablation catheters
  • Electrophysiology medical devices
  • Atrial fibrillation treatment
  • Cardiac arrhythmia therapy

Where CardioFocus is headquartered

Location

Headquarters

HQ city
Marlborough
HQ country
United States
HQ region
North America

Offices2 records

Markets served

CardioFocus business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. PFA Catheter Systems: CardioFocus generates revenue from the sale of pulsed field ablation catheter systems including the Centauri System (CE-marked, commercially available in EU) and investigational systems (QuickShot Nav, OptiShot, CardioWave). Revenue comes from selling ablation catheters, generators, and associated accessories to hospitals and electrophysiology labs.
  2. Distribution Partnerships: Revenue generated through distribution agreements with regional partners including Japan Lifeline (Japan distribution), MicroPort CRM (Spain and Portugal), China Grand Pharmaceutical (China), and BIOTRONIK (European expansion). Partners distribute CardioFocus products in their respective territories.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

CardioFocus product offering

Product offering

Core offering

CardioFocus develops and manufactures pulsed field ablation (PFA) catheter systems and generators for treating cardiac arrhythmias, primarily atrial fibrillation. Its portfolio includes the CE-marked Centauri System (open-platform focal PFA with proprietary WAVE1 waveform) and investigational next-generation systems including QuickShot Nav (large-area focal catheter with map-and-ablate capability), OptiShot (single-shot PFA balloon with endoscopic visualization), and CardioWave (modular multi-catheter generator). The products are sold to hospitals and electrophysiology labs for pulmonary vein isolation procedures.

Product overview

CardioFocus develops a portfolio of Pulsed Field Ablation (PFA) systems for treating cardiac arrhythmias, particularly atrial fibrillation. The portfolio includes the CE-marked Centauri System (open-platform focal PFA with three selectable doses and compatibility with major mapping systems), alongside next-generation investigational systems: QuickShot Nav (large-area focal catheter), OptiShot (single-shot PFA balloon with endoscopic visualization), and CardioWave (modular multi-catheter generator). The company previously offered the HeartLight laser balloon system, which has been succeeded by the PFA portfolio. All systems are designed for pulmonary vein isolation procedures and integrate with established electrophysiology lab workflows.

Differentiator

Problem solved

Functional benefit

Brands

  • Centauri: CE-marked open-platform pulsed field ablation system with custom monopolar waveform for cardiac tissue ablation.
  • QuickShot Nav
  • OptiShot
  • CardioWave
  • HeartLight

Products and services

  • Centauri System An open-platform pulsed field ablation system that integrates into established electrophysiology workflows, delivering a custom monopolar waveform (WAVE1) to create durable lesions safely and efficiently. CE-marked and available in select EU countries, with compatibility across major mapping systems (EnSite X, Carto 3, Rhythmia HDx) and contact force catheters.
  • QuickShot Nav A versatile large-area focal PFA catheter designed to map and ablate with a single, integrated device, uniting mapping and ablation into one streamlined workflow for addressing complex cardiac arrhythmias.
  • OptiShot An ultra-compliant pulsed field ablation balloon with direct endoscopic visualization, enabling circumferential therapy from a single position with a single energy application per vein for pulmonary vein isolation, with anatomy-adaptive balloon architecture.
  • CardioWave System A modular, next-generation PFA generator engineered to power multiple catheter types and clinical applications from a single system, built on proven Centauri technology.
  • HeartLight Endoscopic Ablation System Legacy laser balloon ablation system for treatment of atrial fibrillation, FDA-approved in 2016 and superseded by the company's PFA portfolio.

Quantifiable outcome

  • 89% PV isolation at 3 months using Centauri System across three compatible ablation catheters
  • +5 more outcomes

Companies that use CardioFocus

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles1 record

CardioFocus technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration9 records

Feature7 records

CardioFocus partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered strategic, major and core.

  • LUMA VisionstrategicTechnology or Integration · 7 January 2026Clinical study collaboration in which LUMA Vision's VERAFEYE 4D Imaging Platform was used with CardioFocus ablation systems. Study demonstrated VERAFEYE's ability to integrate high-resolution intracardiac imaging with CardioFocus PFA technology, enabling streamlined two-catheter ablation workflow.
  • StereotaxismajorTechnology or Integration · 13 October 2025Collaboration to advance robotic Pulsed Field Ablation (PFA) technology for cardiac arrhythmias. Joint effort aims to accelerate commercialization of combined robotic PFA system, with preclinical testing showing promising results.
  • BIOTRONIKmajorChannel Partner/ Reseller/ Distributor · 24 July 2025Partnership to expand pulsed field ablation access in Europe. BIOTRONIK will distribute CardioFocus PFA products to expand market reach across European territories.
  • Japan LifelinecoreChannel Partner/ Reseller/ Distributor · 28 February 2025Strategic alliance to advance differentiated PFA system in Japan. Japan Lifeline has been a distribution partner for CardioFocus HeartLight system since 2015, with expanded partnership in 2018 and 2021. The partnership covers distribution of PFA products in Japan.
  • Galvanize TherapeuticscoreTechnology or Integration · 11 January 2024CardioFocus acquired the Electrophysiology Division of Galvanize Therapeutics, including key intellectual property assets that strengthen CardioFocus's PFA technology portfolio.
  • China Grand PharmaceuticalmajorChannel Partner/ Reseller/ Distributor · 4 June 2021Agreement to bring HeartLight X3 System to China. China Grand Pharmaceutical serves as distribution partner for the Chinese market.
  • MicroPort CRMcoreChannel Partner/ Reseller/ Distributor · 11 January 2021Expanded distribution partnership to include Spain and Portugal for HeartLight System distribution. MicroPort CRM covers key European markets.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

CardioFocus competitors and assessment

Company assessment

Regional players

  • BIOTRONIK: European distribution partner for CardioFocus PFA products (announced July 2024) and a broader cardiac rhythm management device manufacturer. Comparable as a CRM and ablation-adjacent player with strong European EP footprint that channels CardioFocus into hospitals.
  • MicroPort CRM: Distribution partner for CardioFocus HeartLight in Spain and Portugal (announced 2021) and broader CRM/cardiac device manufacturer. Comparable as a regional EP-focused player serving Iberian markets where CardioFocus relies on partner-led commercialization.
  • Japan Lifeline: Japanese distribution partner for CardioFocus HeartLight since 2015 and now strategic PFA alliance partner (February 2025). Comparable as a regional EP/cardiac rhythm distributor addressing the Japanese market CardioFocus does not serve directly.

Direct peers

  • Medtronic: Direct competitor via PulseSelect single-shot PFA catheter and the Affera mapping-and-ablation platform acquired in 2022. Medtronic is a major incumbent with global EP sales force and bundled mapping (CardioInsight) competing head-to-head in the PFA category.
  • Boston Scientific: Direct competitor through its Farapulse pulsed field ablation system, which has been one of the earliest commercialized PFA platforms globally. Boston Scientific's scale, US sales force, and integrated mapping (OPAL HDx) compete directly with CardioFocus's Centauri System in EP labs.
  • Johnson & Johnson (Biosense Webster): Direct competitor with the Varipulse pulsed field ablation catheter and CARTO 3 mapping system — a dominant EP franchise worldwide. CardioFocus's Centauri is explicitly compatible with CARTO 3, meaning J&J is both a partner-enabler and a direct competitor in PFA.
  • Abbott: Direct competitor through Abbott's TactiFlex Sensor Enabled and Volt PFA catheters targeting atrial fibrillation ablation. Abbott's EnSite X mapping system is a key integration partner for CardioFocus's Centauri, mirroring the J&J dynamic of partnership plus competition.

Emerging players

  • Acutus Medical: Emerging player in electrophysiology with novel mapping technology and ablation catheter development, including PFA-related programs. Compares to CardioFocus as a smaller, technology-focused EP innovator competing against larger integrated incumbents.
  • Stereotaxis: Robotic magnetic navigation ablation partner of CardioFocus (announced October 2025) developing robotic PFA workflows. Comparable as an EP technology enabler serving the same electrophysiology lab customers CardioFocus targets.
  • Adagio Medical: Emerging player developing ultra-low temperature cryoablation and pulsed field technologies for atrial fibrillation. Adagio's iCLAS catheter and cryo-PFA approach represent an alternative single-shot strategy, partially overlapping with CardioFocus's OptiShot balloon platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights7 records

Customer concentration

CardioFocus social profiles

Digital presence

CardioFocus compliance and trust

Trust signal

Compliance2 records

CardioFocus financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CardioFocus leadership team

Management profile

Number of profiles

Profiles6 records

CardioFocus subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

CardioFocus funding detail

Funding detail

Funding overview

Funding rounds19 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CardioFocus M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CardioFocus

What does CardioFocus do?

CardioFocus develops and manufactures pulsed field ablation (PFA) catheter systems and generators for treating cardiac arrhythmias, primarily atrial fibrillation. Its portfolio includes the CE-marked Centauri System (open-platform focal PFA with proprietary WAVE1 waveform) and investigational next-generation systems including QuickShot Nav (large-area focal catheter with map-and-ablate capability), OptiShot (single-shot PFA balloon with endoscopic visualization), and CardioWave (modular multi-catheter generator). The products are sold to hospitals and electrophysiology labs for pulmonary vein isolation procedures.

Is CardioFocus a public or private company?

CardioFocus is a private company. It is classified as venture growth investor backed and is currently operating.

When was CardioFocus founded?

CardioFocus was founded in 2000. It employs 51 to 100 people.

Where is CardioFocus based?

CardioFocus is headquartered in Marlborough, United States, in the North America region.

How does CardioFocus make money?

Two revenue lines are on record. PFA Catheter Systems are the primary driver. The others are distribution Partnerships.

Who are CardioFocus's main competitors?

Regional players on record are BIOTRONIK, MicroPort CRM and Japan Lifeline. Direct peers are Medtronic, Boston Scientific, Johnson & Johnson (Biosense Webster) and Abbott. Emerging players are Acutus Medical, Stereotaxis and Adagio Medical.

Does CardioFocus have an API?

No public API is recorded for CardioFocus.

What industry is CardioFocus in?

CardioFocus's product category is Cardiac Electrophysiology Devices. Its primary akta.pro industry code is HLAHAFAD, Electrophysiology Mapping & Ablation Systems, with a secondary code of HLAKABAC, Electrophysiology (Heart Rhythm). Its NAICS code is 334510 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogCardioFocus Announces Late-Breaking Data at AF Symposium 2026 and Expands Pulsed Field Ablation Clinical ProgramsCardioFocus announced major advancements across its pulsed field ablation portfolio at the AF Symposium 2026 in Boston, including late-breaking first-in-human data from the VISION AF trial and initiation of global IDE study recruitment for OptiWave and QuickWave systems. The company expanded its Quick AF CE Mark pivotal study to additional European sites in Croatia and Czechia, while also highlighting its next-generation CardioWave PFA generator designed to support multiple catheter systems and integrate with major mapping platforms. Clinical investigators demonstrated the system's capability to perform fluoroless PVI+ procedures and seamless integration with EnSite X, OPAL HDx, and CARTO 3 navigation systems.Business Wire BlogCardioFocus Announces First Enrollments in CE Mark Clinical Trial of QuickShot™ PFA Catheter and CardioWave™ PFA SystemCardioFocus announced the start of its CE Mark clinical trial for new PFA ablation devices in Croatia, enrolling its first patients using the QuickShot™ PFA Catheter and CardioWave™ PFA System. These devices aim to improve treatment for atrial fibrillation by providing rapid, effective ablation with enhanced workflow features.MedTech DiveStereotaxis teams with CardioFocus to develop robotic PFA systemStereotaxis has formed a partnership with CardioFocus to develop a robotic pulsed field ablation system for treating cardiac arrhythmias. The collaboration aims to integrate CardioFocus' Centauri PFA system with Stereotaxis' Magic robotic cardiac ablation catheter, with plans for clinical trials to support authorization and commercialization. Both companies aim to address the complexities of ablation procedures enhanced by robotic capabilities, with Stereotaxis preparing for market entry in the coming years.GlobeNewswireStereotaxis & CardioFocus Collaborate to Advance Robotic Pulsed Field Ablation for Cardiac ArrhythmiasStereotaxis and CardioFocus announced a Collaboration Agreement to advance robotic Pulsed Field Ablation technology for treating cardiac arrhythmias, combining their proprietary technologies to create what they claim will be the first-ever robotic PFA solution. The companies have completed extensive bench and preclinical testing pairing CardioFocus' Centauri PFA System with Stereotaxis' MAGiC robotic cardiac ablation catheter, with recent pivotal preclinical studies demonstrating safe, efficient lesion delivery including deep durable lesions in ventricular tissue. The collaboration aims to advance the joint solution to clinical trials and commercial availability, with first human use anticipated in the coming months pending regulatory compatibility.PR NewswireCardioFocus to Present Data Supporting Next Generation Pulsed Field Ablation Systems at Heart Rhythm 2024CardioFocus announced its participation at Heart Rhythm 2024 in Boston, where it will present new clinical data on its portfolio of pulsed field ablation systems including the HeartLight X3, recently acquired Centauri PFA System, and QuickShot catheter. The company will showcase these products at abstract sessions, a Rhythm Theater presentation, and its exhibit booth. CardioFocus is also highlighting products in development including navigation-enabled QuickShot and a true single shot ultra-compliant PFA balloon.BioSpaceCardioFocus Acquires Electrophysiology Division of Galvanize TherapeuticsCardioFocus, Inc. announced the acquisition of Galvanize Therapeutics' Electrophysiology Technology division, including the CE-marked CENTAURI System and the QuickShot catheter ablation system. This transaction expands CardioFocus's product portfolio with pulsed field ablation technologies and strengthens its presence in the European Union and UK markets. The move positions CardioFocus to accelerate the development of its HeartLight X4 catheter, which is expected to enter human trials in 2024.SecSEC FORM DCardioFocus, Inc. filed a Form D with the Securities and Exchange Commission to report an exempt offering of securities under Rule 506(b). The filing indicates that out of a total offering amount of approximately $31.76 million, roughly $27.16 million had been sold as of the first sale date in February 2023. This regulatory submission formalizes the company's private capital raise activity.PR NewswireCardioFocus Announces Pulsed Field Ablation MilestonesCardioFocus, Inc. announced several milestones toward developing next-generation pulse field ablation (PFA) technology for treating atrial fibrillation, including the formation of a clinical advisory board, filing of key patents, and completion of initial pre-clinical studies. The company is leveraging its HeartLight X3 platform's balloon and direct visualization capabilities to address tissue contact challenges in PFA delivery, with first human use anticipated in early 2023. The clinical advisory board issued a statement supporting the approach, citing promising results from pre-clinical work showing precise lesions delivered circumferentially around pulmonary veins.SecSEC FORM DCardioFocus, Inc. filed a Form D with the SEC on April 12, 2022, announcing an exempt securities offering under Rule 506(b) that commenced sales on March 30, 2022. The company has sold approximately $4 million of its targeted $50 million equity offering to 12 investors so far.PR NewswireCardioFocus to Exhibit and Present Data Supporting HeartLight X3 System at Heart Rhythm 2021CardioFocus, a Marlborough, Massachusetts-based medical device company, announced its participation at the Heart Rhythm 2021 conference (July 28-31, 2021) to showcase its HeartLight X3 System for treating atrial fibrillation, with both in-person presence at Boston Convention & Exhibition Center and virtual attendance options. The company will exhibit at Booth 310 and host multiple physician presentations featuring clinical data from four abstracts supporting the FDA-approved catheter ablation technology. The conference will include hands-on demonstrations using the Mentice Simulator and Ablation Simulation Suite, highlighting the system's RAPID mode for pulmonary vein isolation procedures.